Journal article

Objectively Measured Physical Activity and the Subsequent Risk of Incident Dysglycemia The Australian Diabetes, Obesity and Lifestyle Study (AusDiab)

Anne-Louise Ponsonby, Cong Sun, Obioha C Ukoumunne, Angela Pezic, Alison Venn, Jonathan E Shaw, David W Dunstan, Elizabeth LM Barr, Steven N Blair, Jenny Cochrane, Paul Z Zimmet, Terence Dwyer

Diabetes Care | AMER DIABETES ASSOC | Published : 2011

Grants

Awarded by National Health Medical Research Council (Australia)


Funding Acknowledgements

This study received financial support from The Commonwealth Department of Health and Aged Care, Abbott Australasia Pty Ltd., Alphapharm Pty Ltd., Aventis Pharmaceutical, AstraZeneca, Bristol-Myers Squibb Pharmaceuticals, Eli Lilly (Australia) Pty Ltd., GlaxoSmithKline, Janssen-Cilag (Australia) Pty Ltd., Merck Lipha s.a., Merck Sharp & Dohme (Australia), Novartis Pharmaceutical (Australia) Pty Ltd., Novo Nordisk Pharmaceutical Pty Ltd., Pharmacia and Upjohn Pty Ltd., Pfizer Pty Ltd., Roche Diagnostics, Sanofi Synthelabo (Australia) Pty Ltd., Servier Laboratories (Australia) Pty Ltd., BioRad Laboratories Pty Ltd., HITECH Pathology Pty Ltd., the Australian Kidney Foundation, Diabetes Australia, Diabetes Australia (Northern Territory), Queensland Health, South Australian Department of Human Services, Tasmanian Department of Health and Human Services, Territory Health Services, Victorian Department of Human Services, and Health Department of Western Australia. C.S. is supported by the National Health Medical Research Council (Australia) Postdoctoral Research Fellowship (Grant No. 1013538). D.W.D. is supported by a Victorian Health Promotion Foundation Public Health Research Fellowship. J.E.S. and A.-L.P. are supported by a National Health Medical Research Council Senior Research Fellowship. No other potential conflicts of interest relevant to this article were reported.